Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Pasireotide- and octreotide-treated mice show significantly increased mechanical thresholds on the inflamed side
covalent inhibitor of phosphoinositide 3-kinases (PI3Ks) and Polo-Like kinase 1 (PLK1)
O=C(O[C@H]1CN2CCC1CC2)N(CC1=CC(F)=C(F)C(F)=C1)C1C=C(F)C=CC=1
LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB
InChi: InChI=1S/C16H14O6/c1-22-16-9(3-7-13(19)15(16)21)2-5-11(17)10-4-6-12(18)14(20)8-10/h2-8
RPI-1 Catalog No.:M16910-C Pasireotide- and octreotide-treated mice showRPI 1 is a specific, orally available 2 indolinone Ret tyrosine kinase inhibitor. RPI 1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity. Product information CAS Number: 269730 03 2 Molecular Weight: 297. 31 Formula: C17H15NO4 Chemical Name: (3Z) 3 [(4 hydroxyphenyl)methylidene] 5,6 dimethoxy 2,3 dihydro 1H indol
US$ 18.00
US$ 98.00
US$ 27.00
US$ 32.00
US$ 14.95
US$ 138.00
US$ 12.00
US$ 56.00
US$ 50.00
US$ 21.00
US$ 160.00
US$ 88.00
US$ 128.00
US$ 12.00
US$ 11.95